Plaintiffs bringing US antitrust claims against Boehringer aim to amend complaint
MLex Summary: Plaintiffs bringing US antitrust claims against Boehringer Ingelheim Pharmaceuticals for allegedly manipulating the US Food and Drug Administration’s patent listing process to unlawfully thwart generic competition in multiple markets asked...To view the full article, register now.
Already a subscriber? Click here to view full article